Looking ahead to the period from 2025 to 2035, several key trends and forecasted developments are expected to shape the rail ...
Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), sprung across 15 sites in the U.S. and Canada, successfully met its primary and all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results